Transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis in adults. This evidence note updates evidence note 33 published in March 2011

McIntosh H
Record ID 32013000461
Authors' recomendations: In the only randomised controlled trial (RCT) (PARTNER cohort B), TAVI significantly reduced the risk of death from any cause after 1 year compared with medical management in patients who were unsuitable candidates for surgery. In the only RCT (PARTNER cohort A), TAVI was not inferior to surgical aortic valve replacement with respect to death from any cause after 1 year in candidates for surgery who were at high risk of increased operative complications and death. In the RCT, TAVI was associated with a significantly higher incidence of major vascular complications and neurological adverse events, in both cohorts A and B. There are limited published data on TAVI outcomes beyond 1 year of follow up. There is limited information on the impact of TAVI on quality of life compared with alternative interventions. There are currently no published evaluations of the cost effectiveness of TAVI. Patient selection for TAVI should be undertaken by a multidisciplinary team.
Project Status: Completed
Year Published: 2011
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United Kingdom (Scotland)
MeSH Terms
  • Aortic Valve
  • Cardiac Catheterization
  • Heart Valve Prosthesis Implantation
Organisation Name: Scottish Health Technologies Group
Contact Address: Scottish Health Technologies Group, Delta House, 50 West Nile Street, Glasgow, G1 2NP Tel: 0141 225 6998
Contact Name:
Contact Email:
Copyright: Healthcare Improvement Scotland
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.